Business news for the stock market
Leverkusen, Germany (pta014/12.01.2023/11:30) - Biofrontera AG (FSE: B8F), an international biopharmaceutical company, announces that its wholly owned subsidiary Biofrontera Bioscience GmbH has received a notice of allowance for the application "Photodynamic therapy comprising two light exposures at different wavelengths" (US Appl. No. 17/269,816) by the US patent office USPTO. This patent protects a number of innovations relating a new illumination method to treat dermatological skin diseases with Photodynamic Therapy (PDT).
The patent application refers to a treatment method of PDT, which uses a photosensitizer in combination with light treatment at two different wavelengths. The invention specifically refers to three steps, the first step being the administration of a pharmaceutical composition containing a photosensitizer, an initial exposure to a light with a broader wavelength (e.g., sun light or an equivalent artificial light source), followed by a subsequent exposure to a narrowband light (e.g., BF-RhodoLED®).
"The combination of this treatment protocol with two different wavelengths in this patent also protects our drug Ameluz®. Biofrontera is following a broad patent strategy to protect Ameluz® from generic competition. The granting of the US patent is another important piece of the puzzle in brand protection and also demonstrates that Biofrontera is committed to developing further innovative treatment approaches for PDT," explains Ms. de la Huerta, Chief Financial Officer of Biofrontera AG.
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (Prime Standard). www.biofrontera.com
Forward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "will," "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, including, but not limited to, the risk that the termination of the ADS Level 1 Program or the deregistration with the SEC may not occur or may be delayed, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate